What is Syllable?
Syllable operates at the intersection of artificial intelligence and healthcare services, aiming to enhance communication between patients and medical facilities. The company's core offerings include a sophisticated voice assistant and a web-based assistant designed to streamline interactions, improve patient engagement, and optimize hospital operations. Based in San Jose, California, Syllable is positioned to address critical needs in healthcare accessibility and efficiency.
How much funding has Syllable raised?
Syllable has raised a total of $81.7M across 3 funding rounds:
Series A
$13.7M
Series B
$28M
Series C
$40M
Series A (2018): $13.7M, investors not publicly disclosed
Series B (2021): $28M led by Section 32 and Oak HC/FT
Series C (2022): $40M supported by The TCV, Oak HC/FT, Section 32, and Verily
Key Investors in Syllable
Section 32
Section 32 is a venture capital firm focused on investing in cutting-edge technology, with a strategy targeting innovative startups and emerging technologies to support visionary entrepreneurs.
Oak HC/FT
Oak HC/FT is a premier venture growth-equity fund investing in Healthcare Information & Services and Financial Services Technology, providing strategic counsel and access to an extensive network of industry leaders.
Verily
Verily Life Sciences, an Alphabet subsidiary, focuses on improving health outcomes through data-driven research and digital health solutions, developing software platforms and analytics tools for large-scale biomedical data.
What's next for Syllable?
With substantial backing from prominent investors, Syllable is poised for accelerated growth and innovation. The recent major strategic investment signals confidence in the company's ability to scale its AI-driven solutions across the healthcare sector. Future developments are expected to focus on expanding the capabilities of its voice and web assistants, enhancing data security and compliance within healthcare regulations, and forging new partnerships to broaden its market reach. This infusion of capital will likely fuel further research and development, aiming to solidify Syllable's position as a leader in healthcare technology.
See full Syllable company page
